The idea that shining light on your brain might reduce anxiety and depression sounds far-fetched — until you look at the research. Transcranial photobiomodulation (tPBM) is a growing area of neuroscience, and the evidence for mood-related effects is more substantial than most people realise.
The Mechanism: Light, Mitochondria, and the Brain
Near-infrared wavelengths — particularly 810nm and 1064nm — can penetrate the skull and reach the prefrontal cortex, the brain region most implicated in mood regulation. Once absorbed by cytochrome c oxidase in brain mitochondria, these wavelengths trigger increased ATP production, reduced oxidative stress, and modulation of neurotransmitter systems including serotonin and dopamine.
This is the theoretical basis for mood effects — and it’s supported by a growing body of clinical evidence.
Clinical Evidence for Depression
A 2018 study published in Behavioral and Brain Functions by Cassano et al. examined tPBM (1064nm) in patients with major depressive disorder. The results showed significant reductions in Hamilton Depression Rating Scale scores compared to sham treatment, with no adverse effects reported.
A 2019 pilot RCT in European Psychiatry used 810nm transcranial PBM in patients with major depression and found clinically meaningful reductions in depressive symptoms, with effects persisting at 2-week follow-up.
Clinical Evidence for Anxiety
The anxiety literature is smaller but emerging. Animal studies consistently show anxiolytic effects from NIR tPBM. Human studies are limited but suggest reduction in state anxiety scores following prefrontal tPBM, particularly at wavelengths of 810nm and above.
What Wavelengths Are Used?
Transcranial PBM research primarily uses 810nm and 1064nm. These wavelengths have sufficient penetration depth to reach cortical tissue — shorter wavelengths like 660nm are largely absorbed before reaching the skull.
The MitoADAPT MAX 4.0 is one of the few consumer panels to include both 810nm and 1064nm in its 8-wavelength array, making it suitable for users exploring transcranial applications. Its 11 patent-pending modes include settings designed for targeted use cases.
Important Caveats
The tPBM literature for mood disorders is still early-stage. Most studies are small (20–60 participants), and we’re still establishing optimal protocols, dosing, and patient selection criteria. This isn’t a replacement for established mental health treatment — it’s a potential adjunct, and a promising one.
If you’re using red light therapy for mood, treat it as one component of a broader approach that includes appropriate medical care, sleep, exercise, and nutrition.
The Bottom Line
Transcranial photobiomodulation is one of the most exciting frontiers in RLT research. The early evidence for depression is genuinely compelling. For anxiety, the picture is less clear but biologically plausible. Watch this space — larger RCTs are underway, and the next few years should provide much more definitive answers.
Affiliate Disclosure: Some links on this page are affiliate links. If you purchase through them, we may earn a small commission at no extra cost to you. We only recommend products we have independently evaluated.
